These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26212113)

  • 21. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect.
    Lugini L; Federici C; Borghi M; Azzarito T; Marino ML; Cesolini A; Spugnini EP; Fais S
    J Enzyme Inhib Med Chem; 2016 Aug; 31(4):538-45. PubMed ID: 26018420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells.
    Ihraiz WG; Ahram M; Bardaweel SK
    Acta Pharm; 2020 Jun; 70(2):179-190. PubMed ID: 31955147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB; Duan J; Sridhar R; Damle BD
    Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
    Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
    Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
    Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
    Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.
    Lugini L; Sciamanna I; Federici C; Iessi E; Spugnini EP; Fais S
    Oncotarget; 2017 Jan; 8(3):4147-4155. PubMed ID: 27926505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilization‑associated cell death.
    Takeda A; Takano N; Kokuba H; Hino H; Moriya S; Abe A; Hiramoto M; Tsukahara K; Miyazawa K
    Int J Oncol; 2020 Dec; 57(6):1280-1292. PubMed ID: 33173988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
    Skildum A; Dornfeld K; Wallace K
    Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    Zhang Y; Song S; Yang F; Au JL; Wientjes MG
    J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Zhang Y; Ji W; He L; Chen Y; Ding X; Sun Y; Hu S; Yang H; Huang W; Zhang Y; Liu F; Xia L
    Theranostics; 2018; 8(6):1690-1705. PubMed ID: 29556350
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.
    Chen M; Zou X; Luo H; Cao J; Zhang X; Zhang B; Liu W
    Cell Biol Int; 2009 Sep; 33(9):1008-19. PubMed ID: 19501661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.
    Patel KJ; Tannock IF
    BMC Cancer; 2009 Oct; 9():356. PubMed ID: 19807929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
    Qi X; Chang Z; Song J; Gao G; Shen Z
    Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.